Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression.
Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression.
复制标题
丙咪嗪耐药性复发性抑郁症的治疗，IV：反苯环丙明治疗无反应性双相抑郁症的双盲交叉研究。
DOI：
10.1176/ajp.149.2.195
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Himmelhoch,JM
中科院分区：
文献类型：
--
作者：
Thase,ME;Mallinger,AG;McKnight,D;Himmelhoch,JM
对16名患有无反应性双相抑郁症的门诊患者（年龄18-61岁）进行了一项交叉研究，这些患者在既往丙咪嗪和反苯环丙胺的双盲比较中为无应答者（TCP [JM Himmelhoch et al;参见PA，1978：34071]）。14名患者对至少30 mg/天的TCP或150 mg/天的丙咪嗪治疗4周无反应，2名患者因初始药物不可耐受的副作用而交叉治疗。12例受试者从丙咪嗪交叉至TCP，其中9例对TCP有反应。在抑郁症的测量方面记录了非常显着的改善。4个S从TCP切换到丙咪嗪，但只有1个响应。结果证明了单胺氧化酶（MAO）抑制剂治疗无反应性双相抑郁症的疗效。（PsycINFO数据库记录（c）2016阿帕，保留所有权利）
Conducted a crossover study of 16 outpatients (aged 18–61 yrs) with anergic bipolar depression who were nonresponders in a previous double-blind comparison of imipramine and tranylcypromine (TCP [JM Himmelhoch et al; see PA, Vol 78: 34071]). 14 Ss did not respond to 4 wks of treatment with at least 30 mg/day of TCP or 150 mg/day of imipramine, and 2 Ss were crossed over because of intolerable side effects from the initial drug. 12 Ss were crossed over from imipramine to TCP; 9 of them responded to TCP. Highly significant improvements were documented on measures of depression. Four Ss were switched from TCP to imipramine, but only 1 responded. Results document the efficacy of monoamine oxidase (MAO) inhibitor treatment for anergic bipolar depression.(PsycINFO Database Record (c) 2016 APA, all rights reserved)